McKesson Corporation vs T-Mobile Us Inc — how do they compare? McKesson Corporation trades at $823.07 (market cap $97.35B), while T-Mobile Us Inc trades at $191.73 (market cap $211.72B). The key difference: T-Mobile Us Inc is far larger — about 2.2× McKesson Corporation's market cap, and T-Mobile Us Inc pays the higher dividend (2.09%). Which is the better fit depends on your goals.
| MCK | TMUS | |
|---|---|---|
Market Cap | $97.35B | $211.72B |
Sector | Health | Media |
52-Week High | $995.69 | $259.01 |
52-Week Low | $659.01 | $167.65 |
Enterprise Value | $101.98B | $329.42B |
Dividend Yield | 0.39% | 2.09% |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
T-Mobile US (TMUS) trades at $195.37, up 1.53% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with $88.3B revenue in 2025, 11.65% net margin, and consistent earnings beats in three of the last four quarters. Recent leadership changes and strategic appointments position TMUS for growth amid competitive pressures from satellite internet providers.
TMUS presents a compelling investment case with 83% analyst buy ratings and $238.40 consensus target, offering 22% upside. However, rising debt levels (39.35% debt-to-asset ratio) and Starlink competition pose significant risks. The stock's current RSI levels suggest potential near-term consolidation before further gains.
Trailing returns across standard periods
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →